High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial

Michael Hofman; John Violet; Shahneen Sandhu; Justin Ferdinandus; Sue Ping Thang; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Tim Akhurst; Price Jackson; Mark Scalzo; Scott Williams; Rodney Hicks

Conference Proceedings

High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial

Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Price Jackson, Mark Scalzo, Scott Williams, Rodney Hicks

JOURNAL OF NUCLEAR MEDICINE | SOC NUCLEAR MEDICINE INC | Published : 2018

High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial

University of Melbourne Researchers

Citation metrics

Keywords

STUDY AT MELBOURNE

ABOUT US

CONTACT & MAPS

ALUMNI & FRIENDS

RESEARCH

ENGAGEMENT